Transform how you analyse drug development risk
With the only transparent analysis of drug development risk at the product level.
Thought Leadership
Latest Report
Vantage Pharma, Biotech & Medtech Half-Year Review 2019
Mega-deals mask a significant decline in M&A activity for pharma and medtech The Vantage Half-Year Review 2019 summaries the most significant trends across pharma, medtech and biotech in the first half of 2019. Bristol-Myers Squibb’s $74bn pending purchase of Celgene and Abbvie’s $63bn acquisition of Allergan have taken the headlines,…
Report library
EvaluateMedTech World Preview 2018, Outlook to 2024
Report Highlights Worldwide medtech sales forecast to reach $595 billion by 2024, with a CAGR of 5.6%, anchored by familiar players Neurology set to be the…
EvaluatePharma ワールドプレビュー 2018、2024年への展望 日本語版
分析ハイライト 全世界の処方箋薬売上の年平均成長率は6. 4% (2018-2024年CAGR)で、2024年には1兆2,000億ドルに達すると予測 2024年の処方箋薬売上に占める研究開発費の割合は16.9% オンコロジー領域は年平均12% …
Vantage Pharma, Biotech & Medtech Half-Year Review 2018
Report Highlights Big biotech and big pharma stocks were largely shunned by investors over the first half of the year Demand for new biotech issues shows no sign of…
EvaluatePharma World Preview 2018, Outlook to 2024
Report Highlights Worldwide prescription drug sales accelerate to $1.2 trillion by 2024, as unmet need drives annual compound growth to over 6% R&D spend is…
EvaluatePharma Orphan Drug Report 2018
Report Highlights Worldwide orphan drug sales are forecasted to grow at a CAGR of 11% from 2018-2024 The mean price of the top 100 USA orphan drugs is expected to…
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.